Ned Pagliarulo - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Ned Pagliarulo's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Ned Pagliarulo

Ned Pagliarulo

Verified

Lead Editor, BioPharma Dive

Final Covers

PharmaCovers: Digital health Healthcare

Doesn’t Cover

No gossip.

Journalist Type

-

Seniority Positions

Industries

Medium Formats

-

Content

Total articles 3214

  • J&J keeps forecasts steady as pharma confronts tariff threat

    By Ned Pagliarulo Verified| BioPharma Dive Verified Johnson & Johnson is confident it can manage the impact of tariffs on its pharmaceuticals and medical device businesses this year, announcing Tuesday that it will maintain its financial forecast for the year while raising its sales guidance. J&J, which is the first large drugmaker to report results for the first quarter, expects adjusted earnings per share of $10.60 for 2025.

    By Ned Pagliarulo Verified · BioPharma Dive

    Apr. 15, 2025

  • US launches probe that could set stage for pharma tariffs

    By Ned Pagliarulo Verified, Susanna Vogel Verified| Healthcare Dive Verified First published on Listen to the article 3 minThe Trump administration is investigating the effects of pharmaceutical imports on national security, disclosing Monday a probe that is likely to lay the foundation for sector-wide tariffs in the near future. The investigation, which was announced in a federal notice posted online, appears to be wide-ranging, covering branded and generic medicines, as well the active drug ingredients they contain.

    By Ned Pagliarulo Verified, Susanna Vogel Verified · Healthcare Dive

    Apr. 15, 2025

  • J&J keeps forecasts steady as pharma confronts tariff threat

    By Ned Pagliarulo Verified| BioPharma Dive Verified Johnson & Johnson is confident it can manage the impact of tariffs on its pharmaceuticals and medical device businesses this year, announcing Tuesday that it will maintain its financial forecast for the year while raising its sales guidance. J&J, which is the first large drugmaker to report results for the first quarter, expects adjusted earnings per share of $10.60 for 2025.

    By Ned Pagliarulo Verified · BioPharma Dive

    Apr. 15, 2025

As seen in

Company Info

BioPharma Dive

Banking Dive is a prominent online publication dedicated to the banking industry. It offers in-depth journalism and analysis, providing valuable insights into the latest news, trends, and regulatory changes affecting the sector. As part of Industry Dive, which has merged with TechTarget's technology websites and Informa Tech, Banking Dive has expanded its editorial reach significantly. The platform features a variety of services, including detailed news coverage, a newsletter for subscribers, and deep dive articles that explore specific topics such as regulations and technology's role in banking. Banking Dive caters to professionals in the banking sector, including executives, policymakers, and financial analysts, delivering reliable information to help them navigate the evolving landscape of the industry.

Washington, District of Columbia, United States

+1 202-331-2480